Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2000

View Archived Issues

Ares-Serono advances global R&D program during 1999

Bristol-Myers Squibb reaches significant milestones during 1999

Celltech Chiroscience and Medeva finalize merger

FDA approves new labeling for Hyalgan

Taisho and Takeda to collaborate internationally

Immunomedics reports clinical findings for cancer therapeutic

New formulation of Xatral receives European approvals

Avant and WRAIR to collaborate on HIV vaccine development

Newly issued U.S. patent protects Inhale's dry powder DNA formulations

Immunomedics issued new patent for radioimmunodetection and radioimmunotherapy applications

Beclomethasone Clickhaler approved in France

Carbapenems substituted at the 2-position active against resistant Gram-positive bacteria

Analgesic 1,4-substituted cyclohexyl compounds in development at AstraZeneca

ReVele effectively detects GRP-positive tumors in phase II trial

Licensing opportunity from NIH: 5-lipoxygenase inhibitors as anticancer agents

Neuropharmacological profile of NRA-0160, a unique antipsychotic drug candidate

MCC-134 activates or inhibits K(ATP) channel currrents in a SUR subtype-dependent manner

OPERA will evaluate morbidity and mortality benefits of omapatrilat in at-risk patients

OPC-14523 selected for clinical development as potential antidepressant

Pharmacia selected as name for new company formed by P&U-Monsanto merger

Intranasal IL-12 is a potent adjuvant for enhancing antiviral immunity

American Biogenetic Sciences licenses worldwide rights for ABS-103 to Abbott

Two new anticancer human MAbs enter development at AVI BioPharma

Schering-Plough seeks E.U. approval of Caelyx for treatment of advanced ovarian cancer

Studies at DuPont suggest clinical utility of SF-303 and SK-549 as novel antithrombotics

SciClone initiates phase II study of Zadaxin in hepatitis B

Gene-based osteoarthritis collaboration initiated by Quark and Shionogi

Commencement of clinical trials of Altropane for ADHD diagnosis imminent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 26, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026